Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases.

American journal of pharmacogenomics : genomics-related research in drug development and clinical practice - 1 Jan 2005

van der Kuip Heiko, Wohlbold Lara, Oetzel Carsten, Schwab Matthias, Aulitzky Walter E

Abstract excerpt

A number of highly specific small molecule inhibitors of oncogenic tyrosine kinases have been developed and may potentially improve the treatment of different malignant diseases. However, it became rapidly evident that multiple resistance mechanisms compromise the successful clinical application...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Resistance, Neoplasm
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to Piperazines

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Pyrimidines

Source

Identifiers

PMID: 15813673
DOI: 10.2165/00129785-200505020-00003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-15813673-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases.PMID 15813673Read ↗

Resistance to tyrosine kinase inhibitors: calling on extra forces.Semantic proximity Read ↗

Mechanisms of acquired resistance to tyrosine kinase inhibitorsSemantic proximity Read ↗

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapySemantic proximity Read ↗

Mechanisms of tumor cell resistance to the current targeted-therapy agents.Semantic proximity Read ↗

Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer.Semantic proximity Read ↗

The emergence of resistance to targeted cancer therapeutics.Semantic proximity Read ↗

Molecular Mechanisms of Resistance to Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer CellsSemantic proximity Read ↗

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic StrategiesSemantic proximity Read ↗

Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted TherapySemantic proximity Read ↗

Targeted Therapies in Cancer: To Be or Not to Be, SelectiveSemantic proximity Read ↗

Drug resistance in human cancers - Mechanisms and implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.